The company, founded in 2002, is committed to discovering and developing drug candidates targeting various brain disorders, neurodegenerative diseases, genetic disorders, and cancer. Their clinical-stage products include DR Cysteamine, currently in Phase IIb for nephropathic cystinosis and Phase IIa for non-alcoholic steatohepatitis. They are also developing Convivia for ALDH2 deficiency in Phase IIa trials, DR Cysteamine in Phase II for Huntington's Disease, and Tezampanel and NGX 426 in Phase II for migraine, acute pain, and chronic pain. HepTide for Hepatocellular Carcinoma and Hepatitis C, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases are among their preclinical products. The company collaborates with the University of California, San Diego for clinical studies on DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and patients with cystinosis. They received a significant $85.50MPost-IPO Equity investment on 02 April 2015. Raptor Pharmaceuticals Corp. continues to be a driving force in the biopharma, biotechnology, and health and wellness industries, with headquarters in Novato, California.
Raptor Pharmaceuticals
Embarking on a journey to better health through innovative biotechnology solutions for brain, genetic, and cancer disorders.
General Information
BounceWatch is an independent company data service, not affiliated with Raptor Pharmaceuticals. To contact Raptor Pharmaceuticals, visit raptorpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Raptor Pharmaceuticals compare?
A PDF of Raptor Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Raptor Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Raptor Pharmaceuticals on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
About Raptor Pharmaceuticals
Business keywords: pharmaceuticals, drug development, clinical trials, neurodegenerative diseases, genetic disorders, cancer research, clinical-stage products, preclinical development, University of California San Diego, clinical studies, brain disorders, Huntington's Disease, migraine treatment
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $85.50M | - |
|
02 Apr 2015 |
| Post IPO Debt | $70.00M | 1 |
|
01 Jul 2014 |
| Post IPO Debt | $50.00M | - |
|
20 Dec 2012 |
| Post IPO Equity | $15.00M | 5 |
|
09 Aug 2010 |
| Post IPO Equity | $2.39M | - |
|
14 Sep 2009 |
Raptor Pharmaceuticals Alternatives & Competitors
View All Alternatives
Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders
Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's d...
Pioneering therapeutic solutions to control apoptosis and advance treatments for liver disease, CNS...
Nine Square Therapeutics
FAQ About Raptor Pharmaceuticals
Source: BounceWatch company record for Raptor Pharmaceuticals, https://bouncewatch.com/company/raptor-pharmaceuticals, updated 24 June 2025. When citing, please name BounceWatch and link this page.
